Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) Between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib or Nilotinib as First-Line Therapy in the United Stat ...
May 1, 2018, 00:00
10.1016/j.jval.2018.04.176
https://www.valueinhealthjournal.com/article/S1098-3015(18)30476-5/fulltext
Title :
Comparison of Healthcare Resource Utilization (HRU) and Costs Related to Pleural Effusion (PE) Between Patients Newly Diagnosed with Chronic Myeloid Leukemia (CML) Treated with Dasatinib or Nilotinib as First-Line Therapy in the United Stat ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30476-5&doi=10.1016/j.jval.2018.04.176
First page :
Section Title :
Open access? :
No
Section Order :
1026